Alzforum: Drug News


	Current Papers
	ARF Recommends
	Milestone Papers
	Search All Papers
	Search Comments


	Research News
	Drug News
	Conference News


	AD Hypotheses
		SWAN Knowledge Base
		Current Hypotheses
		Hypothesis Factory
	Forums
		Live Discussions
		Virtual Conferences
		Interviews
	Enabling Technologies
		Workshops
		Research Tools
	Compendia
		AlzGene
		AlzRisk
		Antibodies
		Biomarkers
		Mutations
		Pathways
		Protocols
		Research Models
		Video Gallery
	Resources
		Bulletin Boards
		Conference Calendar
		Grants
		Jobs


	Overview
	Diagnosis/Genetics
	Research
	News
	Profiles
	Clinics


	Companies
	Tutorial
	Drugs in Clinical Trials


	About Alzheimer's
		FAQs
	Diagnosis
		Clinical Guidelines
		Tests
		Brain Banks
	Treatment
		Drugs and Therapies
	Caregiving
		Patient Care
		Support Directory
		AD Experiences


	Member Directory
	Researcher Profiles
	Institutes and Labs


	Mission
	ARF Team
	ARF Awards
	Advisory Board
	Sponsors
	Partnerships
	Fan Mail
	Support Us

Home: News

Drug News

Search by keywords and publication date

Keywords:

any keywords all keywords

Pub Date:

From


Search Results:

1 to 25 of 225 results

Clinical Trials for ALS: Taking Stock of 2009, Looking to 2010
15 January 2010. The Alzforum presents a selection of some of the top ALS trial news of 2009—and looks ahead to 2010 and beyond...

Drug Brief: Generic Aricept Approval—Melts in Your Mouth?
22 December 2009. On 11 December 2009, the U.S. Food and Drug Administration (FDA) announced approval of a generic version of Aricept...

Paper Alert—Phase 3 Tarenflurbil Data Published
17 December 2009. Tarenflurbil, aka flurizan, a γ-secretase modulator that showed promise in early preclinical and clinical trials, failed in Phase 3...

Drug Brief—Adverse Events Prompt Dose Drop in Elan Trial
16 December 2009. It appears that Dublin-based Elan's small molecule drug candidate ELND005 has run into some trouble...

Paper Alert-cum-SfN: Bapineuzumab Published, More AN1792 Presented
19 November 2009. Phase 2 clinical trial data for bapineuzumab, Elan/Wyeth’s humanized monoclonal antibody against amyloid-β, were published...

Research Brief: Glatiramer Slows Progression From High Risk to MS
15 October 2009. A drug used to prevent relapse of multiple sclerosis can also prevent people at risk from developing the full disease, according to a report by The Lancet...

Medical Foods—Food for Thought, But Think Twice
15 October 2009. While the AD field awaits a bona fide drug that goes beyond temporary relief of symptoms, patients may be increasingly open to products claiming even the slightest hint of promise...

Dimebon: Bright Star or Black Hole?
14 October 2009. Dimebon appears as one bright light in a field of less-than-stellar clinical trial results of late...

Medical Foods—Fallback Option for Elusive AD Drug Status?
14 October 2009. Defined by the FDA in 1988, medical foods are a special class of therapeutic agent that fall somewhere in between unregulated food supplements and FDA-approved drugs...

Vienna: New Shoot Among Ashes of Drug Trials
29 July 2009. At the ICAD, news on the drug trials landscape painted a mostly bleak picture, but of course, that’s not the whole story...

NO Joke: Viagra Lessens Aβ, Cognitive Problems in AD Mice
26 June 2009. Giving Alzheimer mice a three-week regimen of Viagra (sildenafil) sharpens their memories and lessens the load of amyloid-β (Aβ) in their brains...

News Brief: What’s Up With Iplex?
22 May 2009. The efficacy of Iplex is unknown; it is untested in clinical trials, untried in mouse models, and, for the most part, unapproved by the Food and Drug Administration...

Drug News Brief: Bapineuzumap Trial Drops Highest Dose
2 April 2009. Elan and Wyeth announced today that two ongoing Phase 3 clinical trials of Bapineuzumab will discontinue the highest planned dose of 2 mg/kg...

Antipsychotics on Trial Again—DART-AD Confirms Increased Mortality
9 January 2009. Antipsychotics are getting pushback as a treatment for behavioral symptoms in AD patients...

IGF-1 Disappoints in Trials for AD, ALS
19 December 2008. November was a dreary month for those who had high hopes for insulin-like growth factor-1 as a treatment for neurodegenerative disorders...

Big Ginkgo Prevention Trial Comes Up Negative
22 November 2008. Older people who are buying and taking ginkgo biloba pills to ward off Alzheimer disease can save their money...

Experts Slam Marketing of Tramiprosate (Alzhemed) as Nutraceutical
10 October 2008. The Canadian pharmaceutical company Bellus Health has begun to sell the would-be prescription drug tramiprosate over the counter as a nutritional supplement...

New Drugs—FDA Approved, But Where’s the Data
4 October 2008. No one would want to make a major investment without carefully weighing the pros and cons...

Chicago: Phase 2 News—Therapeutic Breakfast Food?
29 August 2008. While the media focuses on the next potential billion-dollar pharmaceutical treatment of AD, other investigators have been quietly cooking up alternative approaches...

Chicago: More Phase 2 News—PBT2 and IVIg
28 August 2008. Two anti-amyloid approaches—PBT2 and IVIg—came out with Phase 2 data at ICAD...

Chicago: More News From Phase 2s
27 August 2008. At the International Conference for Alzheimer’s Disease, several investigators presented data on compounds in Phase 2...

Chicago: Flurizan Postmortem
20 August 2008. At the International Conference for Alzheimer’s Disease, investigators reported results on a range of different clinical trials...

Chicago: Lilly’s Antibody Appears to Do No Harm, But Will It Help?
13 August 2008. It’s instructive to learn how pharmaceutical companies are navigating the transition for new experimental AD drugs from Phase 2 to 3...

Chicago: Bapineuzumab’s Phase 2—Was the Data Better Than the Spin?
11 August 2008. The story of how Elan/Wyeth’s antibody therapy fared at the ICAD is one of the stranger tales in AD drug development...

Chicago: Dimebon Safe for 18 Months
8 August 2008. An oral antihistamine has emerged in the race to become the first AD drug with stronger, more lasting benefit than any of the drugs currently available...

1 to 25 of 225 results

Print this page

Email this page

Alzforum News

Text size

Share & Bookmark

Most E-mailed

Most Commented

Last 7 Days

Last 30 Days

Copper Mountain Brief: Rat-a-tat—New Model Comes a Knockin’

Going Wild About the Latest TDP-43 Mouse Models

Copper Mountain: Can CREB Save Memory?

Abnormal Mitochondrial Dynamics—Early Event in AD, PD?

In Veterans, Blood Pressure Meds Delay Dementia

Announcing Alzheimer's Research & Therapy, a new online peer-reviewed journal which publishes open access research articles of outstanding quality in Alzheimer's research.

Check out Geoffrey Beene Gives Back®'s Rocks Stars of Science campaign to bring rock stars and science idols together to share their passion for global health and disease prevention.

The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.

Check out our recent Webinar/Live Discussion: Betwixt and Intermixed—Dementia With Lewy Bodies, held 15 June 2009.

MGluR Agonists and Schizophrenia: 2-D or Not 2-D?

Exploring the Neuregulin-ErbB Pathway

Noncholinergic Approaches to Cognitive Deficits in Schizophrenia

See related news on Alzheimer disease on the BioSpace website.

The AlzRisk Epidemiology Database provides a publicly available collection of published studies on the impact of putative environmental risk factors and protective factors related to Alzheimer disease in longitudinal cohort studies.